Research programme: anti-B7 family-associated protein monoclonal antibodies - CureTech

Drug Profile

Research programme: anti-B7 family-associated protein monoclonal antibodies - CureTech

Alternative Names: Anti-cancer monoclonals; CT 011 analogues; CT-014; Monoclonal antibody cancer therapeutics

Latest Information Update: 15 Sep 2011

Price : $50

At a glance

  • Originator CureTech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Aug 2007 Preclinical development is ongoing
  • 19 May 2005 Preclinical trials in Cancer in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top